Abstract: AIM: To approach the therapeutic effects of mycophenolate mofetil (MMF) in hormonal resistance nephrotic syndromes.METHODS: Patients were diagnosed as nephrotic syndrome and treated with prednisone at the dose of 1 mg·kg ^-1·d ^-1 for over 8 weeks, and 24 patients with unsatisfactory results or were palindromic were selected, and several patients in the 24 patients had been treated with cyclophosphamide or cyclosporine A.All patients were treated with MMF combined with low dose hormone.The initial dose of MMF was 1.0 -1.5 g/d for 3 months, later the dose were reduced, and the maintenance dose of MMF was 0.5 -1.0 g/d, the dose of prednisone was 5 -20 mg/d, the follow-up visit period more than six months. The changes on urine protein, serum albumin, liver function, renal function were compared before and after treatment.RESULTS: Before and after treatment, urine protein decreased from(3.4 ±1.7) g/d to(0.9 ± 0.2) g/d, serum albumin increased from(19.6 ±5.4) g/L to (36.1 ±7.7) g/L.serum creatinine level decreased from(105.7 ±6.4) μmol/L to (90.1 ±5.8) g/L.20 patients(83.3 %) pathogenetic condition were relieved, 15 patients(65.2 %) were with complete remission.5 patients (20.8 %) were partially recovered, and 4 patients (16.6 %) had no response.The adverse effects were observed, including gastrointestinal events (n =8, 33.3 %), bacterial pneumonia (n =4, 16.6 %), herpes zoster (n =1, 4.1 %), hepatic function mild damage (n =3, 12.5 %).CONCLUSION: It is safe and effective to combine MMF with low dose hormone in treatment of hormonal resistance nephrotic syndrome, which could become a therapeutic option for refractory nephrotic syndrome(RNS).

Key words: mycophenolate mofetil, refractory nephrotic syndrome, treatment